Salivary caffeine in Parkinson's disease

Giorgio Leodori, Maria Ilenia De Bartolo, Daniele Belvisi, Alessia Ciogli, Andrea Fabbrini, Matteo Costanzo, Simone Manetto, Antonella Conte, Claudio Villani, Giovanni Fabbrini, Alfredo Berardelli

Research output: Contribution to journalArticlepeer-review


We aimed to investigate salivary caffeine content, caffeine absorption and metabolism in Parkinson's disease (PD) and verify whether salivary caffeine can be used as a biomarker of PD. We enrolled 98 PD patients and 92 healthy subjects. Caffeine and its major metabolite, paraxanthine, were measured in saliva samples collected before and 4 h after the oral intake of caffeine (100 mg). We measured caffeine absorption as the normalized increase in caffeine levels, and caffeine metabolism as the paraxanthine/caffeine ratio. The Movement Disorder Society Unified Parkinson's Disease Rating Scale part III, the Hoehn & Yahr, the presence of motor complications, and levodopa equivalent dose (LED) were assessed and correlated with caffeine levels, absorption, and metabolism. The effects of demographic and environmental features possibly influencing caffeine levels were also investigated. Caffeine levels were decreased in patients with moderate/advanced PD, while caffeine levels were normal in patients with early and de-novo PD, unrelated to caffeine intake. Caffeine absorption and metabolism were normal in PD. Decreased salivary caffeine levels in PD were associated with higher disease severity, longer duration, and the presence of motor complications, no significant association was found with LED. Salivary caffeine decrease correlates with PD progression.

Original languageEnglish
Pages (from-to)9823
JournalSci. Rep.
Issue number1
Publication statusPublished - May 10 2021


Dive into the research topics of 'Salivary caffeine in Parkinson's disease'. Together they form a unique fingerprint.

Cite this